RxDoctor Payments Data

Patrick Larrazabal, MD

Internal Medicine · Ormond Beach, FLNPI 1518923275

Payments from drug & device makers

$2,793in general payments, 2019–2025

Across 144 payments — averaging $19.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$454
  • Bayer$439
  • AstraZeneca$339
  • AbbVie$276
  • Amgen$257
  • Lilly USA, LLC$212
  • plus $817 from 14 others

What the payments were for

  • Food & beverage$2,71397%
  • Education$803%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,793 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$189,290
Medicare patients
312
Services billed
2,111

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide115$179,471
MounjaroTirzepatide112$147,322
FarxigaDapagliflozin Propanediol121$143,265
RybelsusSemaglutide71$119,450
EliquisApixaban92$107,741
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$71,887
KerendiaFinerenone50$65,525
JardianceEmpagliflozin57$65,211
JanuviaSitagliptin Phosphate40$57,750
VraylarCariprazine Hcl28$53,167
XareltoRivaroxaban29$44,888
LinzessLinaclotide35$35,545
MyrbetriqMirabegron21$28,600
TrulicityDulaglutide21$25,095
TradjentaLinagliptin20$23,087

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$454$298,921186 claims
Lilly USA, LLCMounjaro, Trulicity$212$172,416133 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$339$162,428161 claims
PfizerEliquis$95$107,74192 claims
AbbVieVraylar, Linzess, Qulipta$276$100,80074 claims
Boehringer IngelheimJardiance, Tradjenta$102$88,29877 claims
GSKTrelegy Ellipta$27$71,88758 claims
BayerKerendia$439$65,52550 claims
Johnson & JohnsonXarelto$14$44,88829 claims
Astellas Pharma US IncMyrbetriq$65$28,60021 claims
NovartisEntresto$79$21,86318 claims
Kowa Pharmaceuticals America, Inc.Livalo$21$21,28931 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Ormond Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →